Immunovaccine Enters Into Master Services Agreement With Cato

Immunovaccine has entered into a master services agreement with Cato Research Canada (Cato), to assist the company in managing an upcoming Phase 1 clinical trial for DPX-0907, a therapeutic vaccine for ovarian, breast and prostate cancer.

Following the clearance of the investigational new drug application by the FDA, Immunovaccine is expected to initiate a multi-center US phase 1 clinical trial. Cato will perform the study setup, monitoring, project management, data management, and medical writing for the DPX-0907 Phase 1 clinical trials. This will ensure that the protocol and the study conduct adhere to regulatory requirements and that the outcomes are accepted by the FDA.

As part of the agreement, the company had the option to pay a portion of Cato’s service fees through the issuance of common shares. The company has exercised this option and, subject to the final approval of the TSX-Venture Exchange, the company will issue to Cato 167,522 common shares of its capital stock at a price of $0.70 per share.

Randal Chase, president and CEO of Immunovaccine, said: “Cato’s impressive clinical experience combined with the clinical team of highly experienced oncologists is essential for bringing our DPX-0907 vaccine through Phase 1 clinical trials.”

Linda Sutton, COO of Cato, said: “Immunovaccine’s preclinical validation of DPX-0907 is encouraging and we look forward to working with them as both a clinical service provider and shareholder.”